The BAMBI Knockout HEK293T Polyclonal Cells product comprises a population of HEK293T cells that have undergone CRISPR/Cas9-mediated disruption of the BAMBI gene, generating a polyclonal knockout model suitable for investigating TGF-beta/BMP and Wnt signaling pathways. These polyclonal knockout cells are provided as live, adherent cultures and serve as a versatile loss-of-function tool for advanced biomedical research applications, including signal transduction, cancer biology, and fibrosis studies.
The parental HEK293T cell line is an immortalized human embryonic kidney cell line widely utilized for protein expression and viral production due to its high transfection efficiency and robust proliferative capacity. Derived from the HEK293 lineage, HEK293T cells stably express the SV40 large T antigen, which promotes episomal plasmid replication and enhances recombinant protein yields. Their adherent epithelial morphology and consistent growth characteristics make them a standard platform for transient and stable gene expression, functional genomics, and biochemical analyses.
BAMBI (BMP and activin membrane-bound inhibitor) functions as a pseudoreceptor that lacks intracellular kinase activity, competitively inhibiting TGF-beta and BMP signaling by binding to type I receptors such as TGFBR1 and BMPR1A without triggering downstream phosphorylation cascades. This decoy receptor interferes with ligand-induced phosphorylation of SMAD2/3 and SMAD1/5, thereby attenuating transcriptional responses. Additionally, BAMBI modulates Wnt pathway activity through direct interaction with the co-receptor LRP6, influencing beta-catenin (CTNNB1)-dependent transcription. BAMBI expression is regulated by upstream factors including TGF-beta, BMP ligands, Wnt proteins, and TNF-alpha, positioning it as a critical node in the crosstalk between these pathways and the NF-kB signaling axis.
In the HEK293T background, BAMBI knockout removes endogenous inhibition of TGF-beta/BMP and Wnt signaling, creating a sensitized cellular model for studying pathway activation dynamics, receptor-ligand interactions, and downstream effector activity. This system enables researchers to dissect the interplay between BAMBI and critical signaling mediators, such as SMAD2/3 and SMAD1/5 phosphorylation, beta-catenin transcriptional activity, and epithelial-mesenchymal transition (EMT) markers including Snail and Vimentin. The polyclonal nature of the knockout population retains genetic diversity, which may better reflect heterogeneous cellular responses and reduces clonal artifacts often associated with single-cell-derived lines.
Researchers can employ these BAMBI knockout HEK293T polyclonal cells in a wide range of experimental workflows to investigate TGF-beta/BMP-regulated processes, cancer cell invasion and metastasis mechanisms, fibrotic disease progression, and developmental biology. Typical assays include Western blotting for phospho-SMAD2/3 and phospho-SMAD1/5, RT-qPCR analysis of EMT markers, co-immunoprecipitation of BAMBI receptor complexes, luciferase reporter assays for TGF-beta/BMP and Wnt transcriptional activity, and phenotypic migration/invasion assays. Transcriptional profiling via RNA-seq can further elucidate global gene expression changes upon pathway stimulation. For further information, please contact Ascent Research.
